Scroll below to discover ways you can take part at this year's BIO International Convention
Networking Opportunities
Exhibition Reception
Tuesday, June 23
5:00 PM – 6:30 PM
In the Exhibition (Open to All Attendees)
Visit more than 70 pavilions and exhibitor booths while enjoying light food and beverages in the Exhibition. Several exhibitors will have special events at their booth - check the exhibitor list for more information!
Other BIO Receptions
Connect, meet, and network throughout the week. Wrap up the day by connecting with fellow attendees at our networking receptions. Whether you’re looking to expand your network, explore new partnerships, or simply unwind after a full day of BIO Partnering™ meetings and sessions, you'll find great opportunities to connect at BIO 2026!!
Tip: Ensure you have the right registration type to attend some of our receptions. See Registration Types
Curated Sessions
Gain insights from global leaders across the critical areas shaping the future of biotech, including AI and Digital Health, Business Development and Investment, Emerging Opportunities in Global Markets, Next-Generation Biotherapeutics, Science, and Regulatory Affairs.
1:00 PM
-
- AI and Digital Health
Learn from a16z, Insilico, insitro, Isomorphic, Lilly, Microsoft, NVIDIA, and more with a deep-dive kickoff to BIO's four days of AI and Digital Health conversations, -
- AI and Digital Health
28ABCDEThis opening session of the 2026 BIO AI Summit will provide the latest data from Benchling on AI adoption rates across the biotechnology industry including benchmarks by size of organization, by degre ...
)
1:45 PM
-
- Business Development and Investment
30ABCAlzheimer’s disease is one of the greatest challenges facing patients, health systems, and society, affecting over 55 million people worldwide. At the intersection of a growing public health crisis, c ... -
- Emerging Opportunities in Global Markets
29CThe healthcare ecosystem is experiencing an unprecedented transformation fueled by scientific, technological, geopolitical, economic, and demographic changes. Whilst breakthrough innovations are shapi ... -
- Business Development and Investment
25ABCOur industry has faced a variety of geopolitical and economic issues that inject uncertainty into deal-making. We must now navigate an unprecedented wave of legislation, executive orders, and policies ... -
- AI and Digital Health
28ABCDEThis session brings together leaders from pharma, AI technology, life sciences platforms, CROs, and specialized biotech AI to cut through the noise and examine how artificial intelligence is deliverin ... -
- AI and Digital Health
29ABWithin the Asia Pacific Region, Google Health and Health2Sync have partnered with Taiwan's National Health Insurance Administration and AI to stratify diabetes patients at risk of complications and th ... -
- Science and Regulatory Innovation
23BCDespite growing calls for pediatric inclusion, many clinical trials, especially in rare diseases, continue to exclude children or delay their enrollment until late stages. Yet, in many rare diseases, ... -
- Business Development and Investment
5BThis intensive seminar provides biotech leadership teams with a practical, investor-facing playbook for raising institutional private capital. Designed for companies across stages, from early-stage pl ...
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
.jpeg)
)
)
)
3:00 PM
-
- Emerging Opportunities in Global Markets
29CWhen Emerging Biopharma (EBP) companies consider globalization, what criteria guide their choice of markets to enter? In Japan, the evaluation of innovative new drugs has advanced significantly, creat ... -
- AI and Digital Health
29ABAs technology evolves and AI requires more data to improve R&D productivity, the question largely becomes how much do we need versus how much do we want and subsequently, what are the unintended risks ... -
- Business Development and Investment
30ABCIn biotech, success often hinges on spotting opportunities before anyone else does. Some of the industry’s most impactful companies have been built with smart business development regardless of their ... -
- AI and Digital Health
28ABCDEGenerative genomics, using generative AI models to create entirely new, high-fidelity genomic data, represents a major shift in how we understand and apply biology. Large-scale AI models trained on ge ... -
- Business Development and Investment
25ABCThe financing and partnering environment for biotech has shifted significantly in recent years. Investors and partners have increasingly prioritized tangible, de-risked assets that offer compelling th ... -
- Next Generation Biotherapeutics
24BCFor the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promi ... -
- Science and Regulatory Innovation
23BCThe biotech and pharmaceutical sectors are undergoing rapid transformation, driven by advances in digital health, artificial intelligence, personalized treatments, and cell and gene therapies. These b ... -
- Business Development and Investment
32ABSince 2023, the China biotech industry has made great advancements in therapeutic innovation. Initially, innovation was predominantly in oncology; however, since 2025 we have seen more and more projec ... -
- Emerging Opportunities in Global Markets
31ABIn today's competitive biotech landscape, global reach is no longer a luxury—it's a prerequisite for winning. Panelists will reveal how global strategy is the defining competitive differentiator in bi ...
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
3:15 PM
-
- Business Development and Investment
5BEurope offers a uniquely compelling platform for pharmaceutical growth. World class science, deep talent pools, and leading research infrastructures underpin continuous innovation across the value cha ...
)
4:15 PM
-
- Science and Regulatory Innovation
23BCAs the biopharmaceutical industry strives to address areas of high unmet medical need, there is increasing reliance on novel endpoints to accelerate and support drug development. In rare diseases, tra ... -
- AI and Digital Health
28ABCDEThis session will explore how quantum computing is poised to redefine the frontiers of drug discovery by solving complex molecular and optimization problems that exceed the limits of classical computi ... -
- AI and Digital Health
29ABClinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development. Patient recruitment often lags, administrative bo ... -
- Next Generation Biotherapeutics
24BCFor decades, the biotech innovation engine has produced extraordinary breakthroughs in cancer, rare diseases, and metabolic disorders. Yet across vast areas of medicine from preeclampsia to sarcopenia ... -
- Business Development and Investment
25ABCAfter two years of a quiet IPO window, the biotech markets are showing renewed signs of life. A growing number of companies are testing public waters again — but with tighter investor scrutiny, leaner ... -
- Emerging Opportunities in Global Markets
29CThe China-US relationship will have a huge role in shaping the future of global biotech. Yet, this relationship is increasingly defined by both interdependence and tension — with science, supply chain ... -
- Next Generation Biotherapeutics
31ABCardiovascular disease (CVD) remains the world’s leading cause of death, yet policy prioritization and investment continue to lag behind its health and economic impact. This session will explore how g ...
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
.jpeg)
)
.jpg/fit-in/120x9999/filters:no_upscale())
11:00 AM
-
- AI and Digital Health
31ABThe next evolution of AI in biopharma is already here - systems designed not just to analyze data but to make decisions. These “agentic AI” models can set goals, adapt strategies, and generate hypothe ... -
- Business Development and Investment
25ABCAs the next wave of patent cliffs loom, the pressure is on pharma to secure late-stage assets that deliver near-term value. Meanwhile, biotech leaders are navigating tighter capital markets and evolvi ... -
- Business Development and Investment
30ABCAs major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ... -
- Science and Regulatory Innovation
23BCEurope is actively working to improve the clinical research environment, with particular emphasis on supporting biotechnology innovation and adapting to evolving scientific and societal needs. As new ... -
- Business Development and Investment
32ABAI has generated substantial interest across the life sciences industry, yet its practical adoption in commercial forecasting and early asset assessments remains limited. Many organizations continue t ...
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
1:45 PM
-
- AI and Digital Health
31ABAI is redefining what’s possible across industries, and nowhere is the opportunity greater than in life sciences. But unlocking its full power requires more than algorithms — it demands bold new ways ... -
- Business Development and Investment
25ABCMacroeconomic challenges that have hindered biotech IPO activity are subsiding and capital markets are expected to improve later in 2026, especially for early-stage biotech companies. Increased M&A ac ... -
- Business Development and Investment
30ABCThis session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processe ... -
- Science and Regulatory Innovation
23BCRecent changes in FDA’s leadership and approach have caused some concern among industry leaders and patients about the stability, predictability, and reliability of our regulatory framework. While our ... -
- Business Development and Investment
29ABThis data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
3:00 PM
-
- Science and Regulatory Innovation
32ABThis session explores how patient preference studies (PPS) are transforming regulatory strategies in drug development, aligning with the upcoming ICH E22 guideline - the first international guideline ... -
- AI and Digital Health
31ABAI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this ses ... -
- Business Development and Investment
25ABCWomen’s health is now a dynamic arena for innovation, data science, and strategic capital deployment. This session brings together leading investors to discuss where smart capital is flowing and how s ... -
- Business Development and Investment
30ABCAs life sciences innovation becomes increasingly global, many emerging biotech ecosystems continue to face barriers to accessing the capital, infrastructure, and networks that define established hubs ... -
- AI and Digital Health
30DEAI is becoming ubiquitous in biopharma, but no company can unlock its full potential alone. As the industry shifts from "tell me" to "show me," the pressure is on to move beyond the hype and use AI to ...
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
4:15 PM
-
- Business Development and Investment
25ABCAI-enabled discovery and multi-modal, human-centric datasets are driving the next wave of biopharma partnerships. Collaborations are expanding rapidly, characterized by larger upfronts, equity-linked ... -
- Business Development and Investment
30ABCWith federal agencies commitments being uncertain and wavering, many researchers as well as emerging drug and device developers are struggling to find funding or to continue projects. At the same time ... -
- Next Generation Biotherapeutics
32ABThe metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires ther ... -
- AI and Digital Health
31ABCancer immunotherapy has transformed oncology, yet many patients still don't respond or develop resistance to these treatments. Meanwhile, AI has generated unprecedented libraries of potential targets ... -
- Business Development and Investment
28ABCDEPatients are in urgent need of breakthrough treatments, and the global community benefits most when America drives the next generation of biotechnology innovations. However, America’s leadership is in ... -
- Emerging Opportunities in Global Markets
23BCMany Western biopharma leaders look back and wish they had engaged earlier with the China story. A similar inflection point is now unfolding in Korea, and the time to engage early is now. South Korea ...
)
)
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
.jpeg)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
.jpeg)
)
11:00 AM
-
- Business Development and Investment
25ABCThe 36th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotech industry as the operating and regulatory ecosystem is undergoing dramatic changes. ... -
- AI and Digital Health
31ABAI has moved from concept to execution in drug discovery, but turning algorithms into actionable insights requires deep scientific alignment and cross-functional integration. This session brings toget ... -
- Business Development and Investment
30ABCAs the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as compan ... -
- AI and Digital Health
30DEFederated learning is a machine learning approach that trains models across decentralized datasets without pooling patient-level data into a central repository. For biotechnology executives, it can ac ...
)
)
)
)
)
)
.jpeg)
)
)
)
)
12:15 PM
-
- Emerging Opportunities in Global Markets
28ABCDEExplore how Saudi Arabia is building an integrated biotech ecosystem: agile regulation, targeted incentives, national genomics data assets, and enabling infrastructure to become a regional and global ...
)
)
1:45 PM
-
- AI and Digital Health
30DEAlthough artificial intelligence (AI) has existed for decades, recent advances in computational power, data availability, and machine learning models have significantly accelerated its development and ... -
- Next Generation Biotherapeutics
31CLongevity science has entered its execution era. What once sounded speculative now rests on clearer biology, richer human datasets, and maturing toolkits that are pushing longevity from buzzword to bu ... -
- Science and Regulatory Innovation
32ABThe April 2025 Food and Drug Administration Roadmap to Reducing Animal Testing in Preclinical Safety Studies is a signature effort to shift the prevailing drug development paradigm. Aiming to reduce c ... -
- Emerging Opportunities in Global Markets
23BCThis session focuses on shifting from reactive to preventative strategies in managing medicine shortages. Speakers will highlight supply chain resilience, harmonized processes and systems, and innovat ... -
- Business Development and Investment
30ABCThis session will explore ARPA-H’s unique SBIR/STTR funding opportunities and the distinctive commercialization support designed to propel breakthrough companies forward. Attendees will hear firsthand ... -
- Business Development and Investment
25ABCIn recent years, a confluence of global economic, market, and policy shifts have led to the abandonment of more than 1,000 promising treatments in development for rare diseases - many of which deliver ... -
- AI and Digital Health
31ABFor centuries, nature, and particularly the innate immune system, has encoded powerful mechanisms for disease control and repair. Today, artificial intelligence (AI) is reshaping drug discovery by rev ... -
- Business Development and Investment
29ABThe biotech ecosystem is navigating real headwinds — tighter capital, increasingly complex science, and an increasingly unforgiving path from discovery to clinic. But pressure also creates openings. T ...
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
3:00 PM
-
- Business Development and Investment
30ABCThis panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session ... -
- Next Generation Biotherapeutics
31CFor decades, autoimmune disease therapy has been defined by one trade-off - suppressing the immune system to relieve symptoms. That paradigm is now breaking. The 2025 Nobel Prize in Physiology of Medi ... -
- AI and Digital Health
31ABUntil recently, drug discovery has been limited by fundamental practical constraints such as the range of proteins that exist in nature or the availability of samples, time, and funding for experiment ... -
- AI and Digital Health
30DEAI technologies are no longer a peripheral concept in drug discovery – these platforms are a driving force for innovative companies reshaping the way we identify targets, and design, optimize, and val ... -
- Science and Regulatory Innovation
28ABCDEThis session will explore the latest developments at the European Medicines Agency (EMA) regarding review processes, technological trends, and policy innovations via a moderated discussion with Execut ...
.jpeg)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM
-
- AI and Digital Health
31ABArtificial intelligence (AI) has become a widely used label across biotech companies positioning platforms for drug discovery and development. However, what truly defines an AI-marketed platform today ... -
- Business Development and Investment
25ABCEurope's decades-long decline in pharmaceutical R&D and delay in patient access to medicines are the direct result of government policies designed to lower spending on innovative medicines, including ... -
- AI and Digital Health
30DEDeath of expertise in the dawn of AI has been vastly overreported with no sign of its ability to displace creative and disciplined drug discovery teams. Citing Bernstein Research, the Financial Times ... -
- Next Generation Biotherapeutics
29CThe FDA’s new guidance supporting non-animal testing methods is reshaping preclinical drug development, creating unprecedented opportunities for biotech innovation. This session brings together biotec ... -
- Science and Regulatory Innovation
29ABEnacted in 1992, the Prescription Drug User Fee Act (PDUFA) establishes how regulated industry fees support the human drug review program at the Food and Drug Administration (FDA) and associated Agenc ... -
- Business Development and Investment
30ABCBack by popular demand, this session returns with fresh insights for 2026. Health and science executives will learn how to build and deliver an investor-ready story using LaVoieHealthScience’s LHS Fif ... -
- Next Generation Biotherapeutics
31CHeart disease remains the leading cause of death in the United States, with a person dying every 34 seconds from cardiovascular disease, claiming almost one million American lives every year and accou ... -
- Business Development and Investment
28ABCDEThis session will shed light on the recent acquisition of Akero Therapeutics by Novo Nordisk. The two panelists played a key role in forging this deal and will share their perspective on the journey t ...
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
9:00 AM
-
- Business Development and Investment
25ABCIn an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and p ... -
- Next Generation Biotherapeutics
30DEOver the past five decades, the Langer Lab has played a central role in shaping modern biotechnology—founding more than 40 companies and training over 1,000 scientists, many of whom are now professors ...
)
.jpg/fit-in/120x9999/filters:no_upscale())
.jpeg)
)
10:15 AM
-
- Emerging Opportunities in Global Markets
25ABCEurope is taking bold steps in transforming its biotech industry, from strengthening biotech ecosystems, simplifying regulatory framework, and accelerating trial authorizations, to creating better fun ... -
- Science and Regulatory Innovation
23BCSponsors routinely collect patient experience data (PED) to better understand disease areas and ensure development programs meet patient needs. To advance patient-focused drug development effectively, ...
)
)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}